A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316. To evaluate the preliminary efficacy of SHR-1501 alone or in combination with BCG or SHR-1316 in the treatment of NMIBC.

Trial Details

NCT ID
NCT05410730
Phase
PHASE1 / PHASE2
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • SHR-1501
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent in writing;
  • Age ≥ 18 years old, gender is not limited;
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤2;
  • Expected survival time ≥ 2 years;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →